From: Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
------------------------------Time to Death (days)------------------------------ | ||
---|---|---|
Analysis with censoring of patients who began a new therapya | Analysis without censoring of patients who began a new therapyb | |
Median (95% CI), days c | Median (95% CI), days c | |
Overall Survival (N = 74) | 230.0 (143.0, 401.0) | 230.0 (148.0, 330.0) |
Exploratory Analyses | ||
Overall survival by: | ||
M classification | ||
M1a (n = 7) | NE (270.0, NE) | 340.0 (270.0, NE) |
M1b (n = 13) | NE (230.0, NE) | NE |
M1c (n = 54) | 148.0 (116.0, 297.0) | 148.0 (117.0, 239.0) |
Prior chemotherapy | ||
With (n = 40) | 165.0 (118.0, 297.0) | 165.0 (143.0, 297.0) |
Without (n = 34) | 401.0 (138.0, NE) | 340.0 (139.0, NE) |
Dose escalation of talabostat | ||
With (n = 44) | 330.0 (153.0, NE) | 330.0 (165.0, NE) |
Without (n = 30) | 139.0 (81.0, 270.0) | 139.0 (81.0, 230.0) |
Initial cisplatin dose | ||
100 mg/m2 (n = 35) | 230.0 (109.0, NE) | 239.0 (116.0, 401.0) |
75 mg/m2 (n = 39) | 209.0 (148.0, NE) | 209.0 (148.0, 340.0) |